Evaluation of AMG 714 for Vitiligo

(

REVEAL

)

ITN Protocol #:

ITN086AI

Branded Name:

REVEAL

ClinicalTrials.Gov ID:

Treatment Protocol #:

Therapeutic Area:

Autoimmune Disease

Current Status:

Follow-up

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Clinical Trial Physician

NIAID Project Manager

Rho Data Manager

Study Personnel:

Protocol Chair

Brett King, MD PhD brett.king@yale.edu

Work:

Protocol Chair

Patti Tosta ptosta@immunetolerance.org

Work:

415-353-4421

Protocol Chair

Carolyn Bromstead cbromstead@immunetolerance.org

Work:

415-278-0702

Protocol Chair

Laura Cooney, PhD lcooney@immunetolerance.org

Work:

734-274-1149

Protocol Chair

Dawn Smilek, MD PhD dsmilek@immunetolerance.org

Work:

415-353-4308

Protocol Chair

Wendy Gao gaowe@mail.nih.gov

Work:

240-627-3471

Protocol Chair

LaSonia Morgan LaSonia_Morgan@rhoworld.com

Work:

919-595-6379

Admin Links

Shortcuts

ITN Documents

Links